Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Raw Materials: 2019-2024

Historic Raw Materials for Ptc Therapeutics (PTCT) over the last 6 years, with Dec 2024 value amounting to $2.5 million.

  • Ptc Therapeutics' Raw Materials fell 18.04% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 18.04%. This contributed to the annual value of $2.5 million for FY2024, which is 166.60% up from last year.
  • As of FY2024, Ptc Therapeutics' Raw Materials stood at $2.5 million, which was up 166.60% from $952,000 recorded in FY2023.
  • Ptc Therapeutics' 5-year Raw Materials high stood at $2.5 million for FY2024, and its period low was $824,000 during FY2020.
  • For the 3-year period, Ptc Therapeutics' Raw Materials averaged around $1.5 million, with its median value being $1.1 million (2022).
  • Per our database at Business Quant, Ptc Therapeutics' Raw Materials fell by 23.98% in 2022 and then skyrocketed by 166.60% in 2024.
  • Ptc Therapeutics' Raw Materials (Yearly) stood at $824,000 in 2020, then skyrocketed by 72.09% to $1.4 million in 2021, then declined by 23.98% to $1.1 million in 2022, then declined by 11.69% to $952,000 in 2023, then spiked by 166.60% to $2.5 million in 2024.